Abstract:Phosphorylation of tau at Ser (396, 404) (p-tau396,404) is one of the earliest phosphorylation events, and plasma p-tau396,404 level appears to be a potentially promising biomarker of Alzheimer's disease (AD). The low abundance and easy degradation of p-tau in the plasma make the lateral flow assay (LFA) a suitable choice for point-of-care detection of plasma p-tau396,404 levels. Herein, based on our screening of a pair of p-tau396,404-specific antibodies, we developed a colorimetric and surface-enhanced Raman scattering (SERS) dual-readout LFA for the rapid, highly sensitive, and robust detection of plasma p-tau396,404 levels. This LFA realized a detection limit of 60 pg/mL by the naked eye or 3.8 pg/mL by SERS without cross-reacting with other tau species. More importantly, LFA rapidly and accurately differentiated AD patients from healthy controls, suggesting that it has the potential for clinical point-of-care application in AD diagnosis. This dual-readout LFA has the advantages of simple operation, rapid, and ultra-sensitive detection, providing a new way for early AD diagnosis and intervention, especially in primary and community AD screening. Electronic supplementary material: Supplementary material (characterization of AuNPs and 4-MBA@AuNP probe; the optimal 4-MBA load for AuNPs; the optimal K2CO3 volumes for 4-MBA@AuNP-3G5 conjugates; the optimal 3G5 load for 4-MBA@AuNP conjugates; effect of NaCl concentration on 4-MBA@AuNP-3G5 stability; the linear curve of T-line color and SERS intensity versus different p-tau396,404 concentrations; the comparison of colorimetric-based LFA test results and the diagnosis results; Raman intensities and antibody activity of 4-MBA@AuNP-3G5 before and after storage; colorimetric intensity of dual-readout LFA detecting different concentrations of p-tau396,404 protein; sequence of synthesized peptides used in this study; information of the participants in this study; the information of antibodies used in this study) is available in the online version of this article at 10.1007/s12274-022-5354-4.

Entropy-driven Catalysis-Based Lateral Flow Assay for Sensitive Detection of Alzheimer 'S-Associated MicroRNA

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay

A New Strategy for Ultrasensitive Detection Based on Target microRNA-Triggered Rolling Circle Amplification in the Early Diagnosis of Alzheimer's Disease

Integrated Ultrasound‐Enrichment and Machine Learning in Colorimetric Lateral Flow Assay for Accurate and Sensitive Clinical Alzheimer's Biomarker Diagnosis

In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker

Self-calibrating surface-enhanced Raman scattering-lateral flow immunoassay for determination of amyloid-β biomarker of Alzheimer's disease

Ultrasensitive, label-free, electrochemical detection of miRNA-206 in human plasma: A potential biomarker associated with Alzheimer's disease

Implementation of an ultra-sensitive microwell-based electrochemical sensor for the detection of Alzheimer's disease

A sensitive detection assay based on signal amplification technology for Alzheimer's disease's early biomarker in exosome

A Dual-Signal Amplification Strategy Based on Rolling Circle Amplification and APE1-assisted Amplification for Highly Sensitive and Specific Mirna Analysis for Early Diagnosis of Alzheimer's Disease.

Detection of multiplex exosomal miRNAs for clinically accurate diagnosis of Alzheimer's disease using label-free plasmonic biosensor based on DNA-Assembled advanced plasmonic architecture

Ultrasensitive detection of multiple Alzheimer's disease biomarkers by SERS-LFA

Evolution of Detecting Early Onset of Alzheimer's Disease: From Neuroimaging to Optical Immunoassays

Poly-Adenine Assisted Signaling Displaced Probe Ratiometric Electrochemical Aptasensor for Accurate Detection of Alzheimer's Disease Aβ Biomarkers

Accurate and highly sensitive detection of Alzheimer's disease-related extracellular vesicles via förster resonance energy transfer

Enzyme-Assisted Fluorescence Biosensor Based on Circular Single-Stranded DNA Without Group Modification for MicroRNA Detection

Fe3O4/MXene Nanosphere-Based Microfluidic Chip for the Accurate Diagnosis of Alzheimer’s Disease

Ultrasensitive and Point-of-care Detection of Plasma Phosphorylated Tau in Alzheimer’s Disease Using Colorimetric and Surface-Enhanced Raman Scattering Dual-Readout Lateral Flow Assay

Early and In-Stage Diagnosis of Alzheimer’s Disease by the Simultaneous Fluorescent Determination of the Biomarkers miR-501-3p and miR-455-3p with Carbon Quantum Dots in Serum

Ultrasensitive Detection of Alzheimer’s Amyloids on a Plasmonic-Gold Platform

Ultrasound-enhanced Catalytic Hairpin Assembly Capable of Ultrasensitive Microrna Biosensing for the Early Screening of Alzheimer's Disease.